Tagged with US

USA The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines how ALK navigates structural complexity, builds local scale, and prepares its next wave of innovation across immunotherapy and anaphylaxis. The…

USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…

USA Cardiff Advisory’s David H. Crean outlines how the 2026 JP Morgan Healthcare Conference signaled a shift from sector reset to disciplined re-acceleration in global biopharma. Dr Crean explores investor sentiment, capital markets dynamics, M&A and venture activity, and the strategic priorities shaping 2026, highlighting why execution, selectivity, and capital discipline…

USA Crystal S. Denlinger, MD, serves as CEO at the National Comprehensive Cancer Network® (NCCN®), where she oversees the development of evidence-based, expert consensus-driven clinical practice guidelines that shape cancer care across the United States and globally. A practicing medical oncologist with approximately 20 years of clinical experience, Denlinger brings firsthand…

USA Adriana Herrera, CEO of Pierre Fabre Pharmaceuticals Inc, discusses Pierre Fabre’s dedicated expansion into the US market and the unique strategies guiding its next phase of growth. Drawing on more than two decades of leadership experience across global biopharma organizations, Herrera reflects on building a purpose-driven organization, establishing credibility beyond…

USA Dr Carlos Prada, Director of the Edwards Family Division of Genetics and Rare Diseases at Ann & Robert H. Lurie Children’s Hospital of Chicago, discusses how earlier diagnosis, coordinated care pathways, and emerging therapeutic modalities are reshaping outcomes for children and families. From newborn screening and multidisciplinary follow-up to the…

Taiwan Sean Chang, CEO of Locus Cell, explains how his clinical CAR-T background led him to build a Taiwan-based CDMO for advanced cell therapies. The company is scaling Southeast Asia’s largest GMP facility, leveraging Taiwan’s manufacturing discipline, regulatory reforms and global partnerships to deliver high-quality, cost-competitive production bridging academic innovation and…

USA Writing in the January 2026 edition of DIA Global Forum, Mariana Socal and Antonio J. Trujillo from the Johns Hopkins Bloomberg School of Public Health and Rachel Goode of Fresenius Kabi argue  that biosimilars could significantly reduce US drug spending and expand patient access, but that their impact is being…

Europe Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the medicines life cycle, while the pharma sector itself contributes materially to global emissions. Against this backdrop, the European Medicines Agency…

USA Neil F. McFarlane, President and CEO of Zevra Therapeutics, reflects on how his experiences in clinical practice, military service, and leadership roles across biotech and mid-sized pharma come together and led him to this moment. Under McFarlane, Zevra is driven by the urgency of patient needs and engaging with patient…

USA Alberto Santagostino, CEO of AGC Biologics, discusses how the company is positioning itself in an increasingly regionalized CDMO market, the strategic value of its global manufacturing footprint, and the role of technical expertise and long-term partnerships in supporting advanced biologics and cell and gene therapy programs. Santagostino goes on to…

USA Loretta Beine, Senior Director of Industry Development for Life Sciences, Empire State Development (ESD) explains the organization’s broader role in growing New York State’s life sciences sector beyond direct funding. As New York State’s chief economic development agency, ESD focuses on supporting startups, attracting new investment, and job creation to…